Navigation Links
ePharmaSolutions Announces the Deployment of its Enterprise Clinical Trial Portal for Two Global Biopharmaceutical Companies
Date:8/24/2011

CONSHOHOCKEN, Pa., Aug. 24, 2011 /PRNewswire/ -- ePharmaSolutions announced the successful deployment of its Enterprise level Clinical Trial Portal (CTP) for a top five global pharmaceutical company on more than 900 studies to 90 countries and a second client deployment scheduled for September 2011.

Clinical Trial Portals help streamline and accelerate the clinical development process for sponsors, study sites and third party vendors by providing a common technology platform from which to conduct their trials.  Historically these portals were deployed at the study level, resulting in measurable improvements in time and cost for that study.  Today, biopharmaceutical companies are standardizing on single vendors to provide these portal solutions across the enterprise to help realize the time and cost savings across the enterprise while simplifying the process for study teams and site users.

"We are seeing more of our sponsors and CRO partners migrate from single study workspaces to enterprise CTP deployments this year than ever," stated Lance Converse, ePharmaSolutions' Founder and CEO.  "Enterprise deployments of the CTP help force the standardization of business processes across the clinical development lifecycle while reducing cost and accelerating timelines," added Converse.

ePharmaSolutions' Clinical Trial Portal is currently used by more than 235,000 users in 120 countries and helps biopharmaceutical companies improve and accelerate site activation, study training, safety letter distribution, and patient recruitment while integrating all of the third-party vendor applications (EDC, IXRS, Labs, etc.) to help centralize study management/reporting and provide users with one website and one set of credentials for all of their clinical study needs.

"Enterprise deployments typically include integrations with the clients' CTMS, EDC and IXRS systems, which can significantly reduce the amount of data entry required across the various systems used to conduct trials in today's technology driven clinical trials environment," stated Steven Beales, ePharmaSolutions Vice President of Information Technology.  "The integrations allow the study teams to add or edit a user in the CTP and authenticate that change to all of the systems used in the study, eliminating redundant manual data entry and multiple account registrations forms," Beales added.

The typical cost saving for using the Clinical Trial Portal on a one year 75 site global oncology study can exceed $1 million dollars (US) when compared to the traditional cost of paper based site feasibility, study document completion, in-person training and overnighted safety letter distribution.

About ePharmaSolutions

ePharmaSolutions is a leading provider of technology-based clinical services that helps improve the way sites are selected, trained, activated and managed to exceed enrollment goals.   ePharmaSolutions won the 2009 Bio-IT World Award for best clinical trial technology and has activated and trained more than 235,000 clinical researchers in 120 countries for the top 20 pharmaceutical companies in the world.  ePharmaSolutions is headquartered in Philadelphia with offices in London. For more information visit www.epharmasolutions.com or call Lance Converse at 610-832-9915.  Follow us on LinkedIn and Facebook.


'/>"/>
SOURCE ePharmaSolutions
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ePharmaSolutions Clinical Trial Investigator Portal Wins Bio-IT World 2009 Best Practice Award
2. ePharmaSolutions Launches New Version of Electronic Monitor Visit Report Application With Industry-Leading Online and Offline Capabilities
3. ePharmaSolutions Launches Major Release of Its Global Safety Letter Distribution and Tracking Application in More Than 90 Countries
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017   Pulmatrix, Inc . (NASDAQ: PULM), a ... serious pulmonary diseases, today announced that it has added two ... and asthma to its Scientific Advisory Board . ... Richard B. Moss , MD, former chief of the Pediatric ... Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... , March 27, 2017 ... to reach USD 16.0 billion by 2025, according to ... growing prevalence of chronic diseases is anticipated to be ... analyzers, which thereby widens the scope for growth during ... and bariatric population, which is highly susceptible to chronic ...
(Date:3/27/2017)... BOSTON , March 27, 2017  Allergan ... and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical ... innovative therapies based upon tetracycline chemistry, announced that ... the treatment of moderate to severe acne met ... a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with ...
Breaking Medicine Technology:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... announces today that the University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® ... Western Pennsylvania. , The program, developed in association with efforts by the American ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
(Date:3/28/2017)... ... 2017 , ... In its ongoing effort to educate consumers ... and published an informational resource that addresses frequently asked questions. , “ ... site’s team of third party administrator (TPA) contributors regularly receives as employers, benefit ...
(Date:3/28/2017)... Santa Monica, CA (PRWEB) , ... March 28, ... ... expert, Dr. Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer ... newest gastric balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s ...
(Date:3/28/2017)... ... ... a common and unwelcomed occurrence in people of all ages, genders and ethnicities. Dermatologist Dr. ... of dealing with excess skin oil. “Oily skin is a challenge to many of my ... the oily shine while keeping the skin fresh and clean,” says Dr. Au. , What ...
Breaking Medicine News(10 mins):